Drug Profile
Cetilistat
Alternative Names: ATL-962; AZM-119; Cametor; ObleanLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Alizyme
- Developer Alizyme; Takeda
- Class Benzoxazines; Obesity therapies; Small molecules
- Mechanism of Action Lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Obesity
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 17 Jul 2018 Takeda and Norgine agree to terminate its licence and development agreement for Cetilistat in Japan
- 20 Jun 2015 Launched for Obesity in Japan (PO)
- 20 Jun 2015 No recent reports of development identified - Phase-II for Obesity in Europe and USA (PO)